{"id":23101,"date":"2023-01-05T01:42:00","date_gmt":"2023-01-04T17:42:00","guid":{"rendered":"https:\/\/flcube.com\/?p=23101"},"modified":"2025-03-03T15:30:04","modified_gmt":"2025-03-03T07:30:04","slug":"duality-biologics-licenses-adc-platform-to-denmarks-adcendo-for-mesenchymal-tumor-program","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=23101","title":{"rendered":"Duality Biologics Licenses ADC Platform to Denmark&#8217;s Adcendo for Mesenchymal Tumor Program"},"content":{"rendered":"\n<p>Duality Biologics, a developer of novel modality drugs operating in the United States and China, has announced a technology license agreement with Denmark-based Adcendo ApS. Under the agreement, Adcendo has been granted a license to use Duality\u2019s antibody drug conjugate (ADC) platform, DITAC, in its mesenchymal tumor product uPARAP program. In return, Adcendo will pay an undisclosed upfront fee, milestone payments, and tiered royalties.<\/p>\n\n\n\n<p><strong>Company Overview and Pipeline<\/strong><br>Founded in January 2020, Duality Biologics focuses on oncology and autoimmune diseases, boasting a product pipeline consisting of over 10 best-in-class and first-in-class bispecific antibodies (BsAbs) and ADCs. The company&#8217;s innovative platform, DITAC, is designed to enhance the development of ADCs for various cancer indications. Adcendo, on the other hand, specializes in the research and development of novel ADCs for the treatment of cancers, with a focus on leveraging innovative technologies to improve patient outcomes.<\/p>\n\n\n\n<p><strong>Adcendo&#8217;s Financing and Development<\/strong><br>Adcendo raised EUR 51 million (USD 54.1 million) in a Series A financing round in 2021, with investors including Novo Holdings, Ysios Capital, RA Capital Management, HealthCap, and Gilde Healthcare. This significant funding underscores Adcendo&#8217;s commitment to advancing its pipeline of ADCs and addressing significant unmet needs in oncology.<\/p>\n\n\n\n<p><strong>Future Outlook<\/strong><br>The technology license agreement between Duality Biologics and Adcendo highlights the growing collaboration between innovative biotech companies to address challenging oncology indications. By leveraging Duality&#8217;s DITAC platform, Adcendo aims to enhance the development of its uPARAP program, potentially offering new treatment options for patients with mesenchymal tumors. This partnership underscores the commitment of both companies to advancing cancer therapies and improving patient care.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Duality Biologics, a developer of novel modality drugs operating in the United States and China,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,2364,16,232,3795,28,25],"class_list":["post-23101","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-adc-xdc","tag-adcendo-aps","tag-cancer","tag-duality-biologics","tag-duality-biotherapeutics","tag-multi-specific-antibodies","tag-potential-first-in-class"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Duality Biologics Licenses ADC Platform to Denmark&#039;s Adcendo for Mesenchymal Tumor Program - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Duality Biologics, a developer of novel modality drugs operating in the United States and China, has announced a technology license agreement with Denmark-based Adcendo ApS. Under the agreement, Adcendo has been granted a license to use Duality\u2019s antibody drug conjugate (ADC) platform, DITAC, in its mesenchymal tumor product uPARAP program. In return, Adcendo will pay an undisclosed upfront fee, milestone payments, and tiered royalties.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=23101\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Duality Biologics Licenses ADC Platform to Denmark&#039;s Adcendo for Mesenchymal Tumor Program\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=23101\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-04T17:42:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-03T07:30:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23101#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23101\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Duality Biologics Licenses ADC Platform to Denmark&#8217;s Adcendo for Mesenchymal Tumor Program\",\"datePublished\":\"2023-01-04T17:42:00+00:00\",\"dateModified\":\"2025-03-03T07:30:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23101\"},\"wordCount\":278,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Adcendo ApS\",\"Cancer\",\"Duality Biologics\",\"Duality Biotherapeutics\",\"Multi-specific antibodies\",\"Potential first-in-class\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23101#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23101\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=23101\",\"name\":\"Duality Biologics Licenses ADC Platform to Denmark's Adcendo for Mesenchymal Tumor Program - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-01-04T17:42:00+00:00\",\"dateModified\":\"2025-03-03T07:30:04+00:00\",\"description\":\"Duality Biologics, a developer of novel modality drugs operating in the United States and China, has announced a technology license agreement with Denmark-based Adcendo ApS. Under the agreement, Adcendo has been granted a license to use Duality\u2019s antibody drug conjugate (ADC) platform, DITAC, in its mesenchymal tumor product uPARAP program. In return, Adcendo will pay an undisclosed upfront fee, milestone payments, and tiered royalties.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23101#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23101\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23101#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Duality Biologics Licenses ADC Platform to Denmark&#8217;s Adcendo for Mesenchymal Tumor Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Duality Biologics Licenses ADC Platform to Denmark's Adcendo for Mesenchymal Tumor Program - Insight, China&#039;s Pharmaceutical Industry","description":"Duality Biologics, a developer of novel modality drugs operating in the United States and China, has announced a technology license agreement with Denmark-based Adcendo ApS. Under the agreement, Adcendo has been granted a license to use Duality\u2019s antibody drug conjugate (ADC) platform, DITAC, in its mesenchymal tumor product uPARAP program. In return, Adcendo will pay an undisclosed upfront fee, milestone payments, and tiered royalties.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=23101","og_locale":"en_US","og_type":"article","og_title":"Duality Biologics Licenses ADC Platform to Denmark's Adcendo for Mesenchymal Tumor Program","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=23101","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-01-04T17:42:00+00:00","article_modified_time":"2025-03-03T07:30:04+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=23101#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=23101"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Duality Biologics Licenses ADC Platform to Denmark&#8217;s Adcendo for Mesenchymal Tumor Program","datePublished":"2023-01-04T17:42:00+00:00","dateModified":"2025-03-03T07:30:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=23101"},"wordCount":278,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Adcendo ApS","Cancer","Duality Biologics","Duality Biotherapeutics","Multi-specific antibodies","Potential first-in-class"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=23101#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=23101","url":"https:\/\/flcube.com\/?p=23101","name":"Duality Biologics Licenses ADC Platform to Denmark's Adcendo for Mesenchymal Tumor Program - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-01-04T17:42:00+00:00","dateModified":"2025-03-03T07:30:04+00:00","description":"Duality Biologics, a developer of novel modality drugs operating in the United States and China, has announced a technology license agreement with Denmark-based Adcendo ApS. Under the agreement, Adcendo has been granted a license to use Duality\u2019s antibody drug conjugate (ADC) platform, DITAC, in its mesenchymal tumor product uPARAP program. In return, Adcendo will pay an undisclosed upfront fee, milestone payments, and tiered royalties.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=23101#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=23101"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=23101#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Duality Biologics Licenses ADC Platform to Denmark&#8217;s Adcendo for Mesenchymal Tumor Program"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23101","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23101"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23101\/revisions"}],"predecessor-version":[{"id":23102,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23101\/revisions\/23102"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23101"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23101"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23101"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}